

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon-lambda for the treatment of COVID-19 in outpatients.

Supplementary Appendix

Supplemental Methods	3
Supplemental Figure 1	4
Supplemental Figure 2	5
Supplemental Figure 3	6
Supplemental Figure 4	7
Supplemental Figure 5	8
Supplemental Table 1	9
Supplemental Table 2	10
Supplemental Table 3	11

Supplemental Methods

SARS-CoV-2 Viral Load Testing

A self-collected mid-turbinate swab was obtained. Samples were inactivated and viral nucleic acid was extracted using the NucliSENS EasyMAG platform (bioMerieux, Marcy-l'Etoile, France), and real-time reverse-transcriptase PCR was performed on the Rotorgene Q (Qiagen, Hilden, Germany) using the primers and probes for the SARS-CoV-2 E gene^{24,25}. To generate standard curves, dilutions of a synthetic plasmid containing a segment of the E-gene were used (GenScript, USA). Samples with either no Ct value or a value that was below the level of quantification were counted as negative. For the purposes of calculation, values below the limit of quantification (~20 copies/mL) were given an arbitrary value of 10 copies/mL.

Figure S1. Time to viral clearance in those with baseline viral load $\geq 10E6$ copies/mL.

The time to undetectable SARS-CoV-2 RNA is shown for the peginterferon-lambda and the placebo group for participants with a baseline viral load above $10E6$ copies/mL. The curves are compared using the log-rank test and the median time to clearance with 95% CI is shown for each group.

Figure S2. Proportion negative for SARS-CoV-2 RNA over time and mean absolute and change in SARS-CoV-2 viral load over time in those with detectable SARS-CoV-2 at baseline.

The proportion of patients negative for SARS-CoV-2 RNA per day post-injection in those with a detectable viral load at baseline (Panel a) with the mean SARS-CoV-2 RNA viral load (Panel b) and log decline from baseline (Panel c) over time in participants with a detectable baseline viral load in the peginterferon-lambda treatment (n=25) and placebo groups (n=20).

*Panel b: Difference at Day 7 $p=0.042$

*Panel c: Difference at Day 5 $p=0.036$ and Day 7 $p=0.006$

Figure S3. Odds ratio for clearance by Day 7 with peginterferon-lambda vs placebo, controlled for individual baseline covariates, in those with baseline viral load $\geq 10E6$ copies/mL

Forest plot showing odds ratio with 95% CI for the odds of clearance by Day 7 with peginterferon lambda treatment compared to placebo, controlled for each individual (bivariate) covariate.

Figure S4. Presence of SARS-CoV-2 antibodies over time stratified by baseline viral load.

The proportion of individuals with positive anti-SARS-CoV-2 S protein IgG antibodies per day post-injection, stratified by baseline viral load above or below 10E6 copies/mL.

Figure S5. Self-collected oral temperature measurements.

Self-collected oral temperature measurements on days 0, 2, 3, 4, 5, 6, 7, 10, 12 and 14 separated into $<38^{\circ}$ Celsius, $38-39^{\circ}$ Celsius and above 39° Celsius stratified by group.

Table S1. Residual SARS-CoV-2 RNA levels at Day 7 post-treatment in those with baseline viral loads above and below 10E6 copies/mL

Baseline Viral Load	Residual Baseline Viral Load at Day 7 in Copies/mL	
	Peginterferon-Lambda	Placebo
≥ 10E6 copies/mL	n=4/19 (21%) 2.74E3 4.59E3 7.95E3 8.58E5	n=10/16 (62.5%) 1.61E1 3.10E2 5.10E3 4.28E4 1.46E5 1.66E5 2.62E5 4.17E5 6.49E5 6.40E6
< 10E6 copies/mL	n=1/11 (9%) 2.41E3	n=1/14 (7%) 1.82E3

Table S2. Association between peginterferon-lambda treatment vs placebo with specific symptom categories and with symptom evolution over time. Results shown for all participants and stratified by baseline viral load.

Symptom Category	Change in severity (day)	All samples		Baseline Viral Load $\geq 10E6$ copies/mL		Baseline Viral Load $< 10E6$ copies/mL	
		OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
All Symptoms							
	Peginterferon-lambda	0.71 (0.61, 0.82)	<.0001	0.74 (0.62, 0.88)	0.0007	0.68 (0.53, 0.87)	0.0024
	Placebo	0.64 (0.55, 0.75)	<.0001	0.60 (0.48, 0.74)	<.0001	0.76 (0.60, 0.96)	0.0187
	<i>Difference in decline</i>		0.32		0.10		0.46
Fever/Systemic							
	Peginterferon-lambda	0.72 (0.62, 0.84)	<.0001	0.77 (0.67, 0.90)	0.0008	0.64 (0.53, 0.77)	<.0001
	Placebo	0.60 (0.49, 0.73)	<.0001	0.64 (0.52, 0.77)	<.0001	0.55 (0.43, 0.69)	<.0001
	<i>Difference in decline</i>		0.06		0.06		0.24
Respiratory							
	Peginterferon-lambda	0.64 (0.51, 0.80)	<.0001	0.70 (0.55, 0.88)	0.002	0.48 (0.26, 0.91)	0.024
	Placebo	0.52 (0.39, 0.69)	<.0001	0.58 (0.42, 0.78)	0.0004	0.41 (0.20, 0.83)	0.013
	<i>Difference in decline</i>		0.19		0.29		0.61
Gastrointestinal							
	Peginterferon-lambda	0.92 (0.75, 1.15)*	0.47	0.92 (0.83, 1.01)*	0.091	0.98 (0.74, 1.3)*	0.90
	Placebo	0.57 (0.42, 0.77)	0.0003	0.53 (0.41, 0.69)	<.0001	0.61 (0.42, 0.9)	0.013
	<i>Difference in decline</i>		0.0004		0.0001		0.0001
Musculoskeletal							
	Peginterferon-lambda	0.54 (0.35, 0.83)	0.005	0.51 (0.33, 0.8)	0.003	0.63 (0.46, 0.85)	0.003
	Placebo	0.50 (0.32, 0.77)	0.002	0.48 (0.31, 0.75)	0.001	0.48 (0.20, 1.17)	0.11
	<i>Difference in decline</i>		0.70		0.81		0.57
Skin							
	Peginterferon-lambda	0.89 (0.57, 1.38)	0.59	0.79 (0.37, 1.67)	0.53	0.40 (0.02, 9.51)	0.37
	Placebo	0.88 (0.57, 1.35)	0.56	0.50 (0.16, 1.60)	0.24	0.91 (0.73, 1.13)	0.22
	<i>Difference in decline</i>		0.96		0.19		0.15
Neurologic/Vascular							
	Peginterferon-lambda	0.68 (0.47, 0.98)	0.037	0.72 (0.53, 0.98)	0.034	0.63 (0.48, 0.83)	0.001
	Placebo	0.60 (0.36, 0.98)	0.043	0.63 (0.43, 0.93)	0.019	0.51 (0.34, 0.76)	0.001
	<i>Difference in decline</i>		0.52		0.5		0.32
Mood							
	Peginterferon-lambda	0.59 (0.29, 1.20)	0.14	0.64 (0.35, 1.19)	0.16	0.56 (0.30, 1.07)	0.077
	Placebo	0.34 (0.12, 0.98)	0.046	0.38 (0.13, 1.10)	0.074	0.52 (0.29, 0.93)	0.029
	<i>Difference in decline</i>		0.14		0.20		0.88

Table S3. The specific severe symptoms reported by participants in each treatment group.

PegIFN Lambda	ID 3	ID 18	ID 9	ID 15	ID 31	ID 47	ID 52
Day 0	throat			smell	smell	smell	smell
Day 0.5	throat					smell	
Day 1					smell	smell	
Day 2	fever				smell	smell	
Day 3	cough					smell	
Day 4							
Day 5			smell				
Day 6		cough, SOB	smell				
Day 7							
Day 10			smell				
Day 12			smell				
Day 14		cough, SOB					

Placebo	ID 5	ID 11	ID 16	ID 27	ID 33	ID 51	ID 60
Day 0	chills		fever, smell, nausea	fatigue	cough, fever, chills, nausea, vomit	smell	
Day 0.5					cough, throat	fatigue, headache	
Day 1					cough, fever, chills, throat, myalgia, abdo, vomit	smell	
Day 2			fatigue, nausea			fatigue, smell	
Day 3			fatigue, nausea			fatigue, smell	
Day 4		fatigue	fatigue				
Day 5		fatigue					cough
Day 6					diarrhea		
Day 7							
Day 10							
Day 12							
Day 14							

Smell – loss of sense of smell/taste, SOB – shortness of breath; abdo – abdominal pain